Advertisement
UK markets closed
  • FTSE 100

    8,252.91
    +29.57 (+0.36%)
     
  • FTSE 250

    21,202.89
    +13.98 (+0.07%)
     
  • AIM

    786.17
    +4.64 (+0.59%)
     
  • GBP/EUR

    1.1903
    +0.0024 (+0.21%)
     
  • GBP/USD

    1.2990
    +0.0075 (+0.58%)
     
  • Bitcoin GBP

    45,205.53
    +436.32 (+0.97%)
     
  • CMC Crypto 200

    1,225.53
    +26.96 (+2.25%)
     
  • S&P 500

    5,615.35
    +30.81 (+0.55%)
     
  • DOW

    40,000.90
    +247.15 (+0.62%)
     
  • CRUDE OIL

    82.18
    -0.44 (-0.53%)
     
  • GOLD FUTURES

    2,416.00
    -5.90 (-0.24%)
     
  • NIKKEI 225

    41,190.68
    -1,033.34 (-2.45%)
     
  • HANG SENG

    18,293.38
    +461.05 (+2.59%)
     
  • DAX

    18,748.18
    +213.62 (+1.15%)
     
  • CAC 40

    7,724.32
    +97.19 (+1.27%)
     

Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Compass Pathways
Compass Pathways

LONDON, June 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference at 7:00 am ET on June 27, 2024. The company will also participate in a panel discussion titled “Commercialization of Novel Compounds in Psychiatry” at 12:00pm ET on June 27, 2024.

A live audio webcast of these events will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following such event. For more information, please visit investor section of compasspathways.com.

About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin treatment, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). We have commenced a phase 3 clinical program of COMP 360 psilocybin treatment in TRD, the largest randomised, controlled, double-blind psilocybin treatment clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also conducting a phase 2 clinical study of COMP360 psilocybin treatment for anorexia nervosa. Compass is headquartered in London, UK, with offices in New York and San Francisco in the United States. Our vision is a world of mental wellbeing. www.compasspathways.com

ADVERTISEMENT

Availability of other information about Compass Pathways
Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Enquiries
Media: Sally Bain, sally.bain@compasspathways.com, + 1 781 458 0443
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324